✦ LIBER ✦

P215A Cost–benefit analysis of a 21-gene recurrence score for early stage breast cancer in Singapore

✍ Scribed by G. de Lima Lopes; R. Chien; J.C. Hornberger

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN13 COST-BENEFIT ANALYSIS OF A 21-GENE

✍ de Lima Lopes, G; Chien, R; Hornberger, J 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB

PCN158 TREATMENT DECISION CHANGE WITH 21

✍ R Chien; J Hornberger 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

Cost-effectiveness of a 21-gene recurren

✍ Malek B Hannouf, Bin Xie, Muriel Brackstone, Gregory S Zaric 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 314 KB

Cost Effectiveness of a 21-Gene Recurren

✍ Hannouf, Malek B.; Xie, Bin; Brackstone, Muriel; Zaric, Gregory S. 📂 Article 📅 2013 🏛 Springer International Publishing AG 🌐 English ⚖ 442 KB

Prognostic value of biologic subtype and

✍ Lawrence J. Solin, Robert Gray, Lori J. Goldstein, Abram Recht, Frederick L. Bae 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 536 KB

PM1 RISK-BENEFIT FRAMEWORK FOR EVALUATIO

✍ J Roth; D Veenstra 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB